Always read the label and follow the directions for use.
Philips medical devices should only be used by physicians and teams trained in interventional techniques, including training in the use of this device. Products subject to country availability. Please contact your local sales representative. Philips reserves the right to change product specifications without prior notification.
Phoenix atherectomy system is distributed by InterMed in New Zealand.
*The Phoenix Atherectomy 1.5 mm Tracking Catheter is indicated for vessels 2.0 mm in diameter or above. The Phoenix Atherectomy 1.8 mm Tracking Catheter is indicated for vessels 2.5 mm in diameter or above. The Phoenix Atherectomy 2.2 mm Tracking, 2.2 mm Pre-Deflected, and 2.4 mm Pre-deflected Catheters are indicated for vessels 3.0 mm in diameter or above. 1.5 mm, 1.8 mm, and 2.2 mm Tracking Catheters and 2.2 mm Pre-deflected Catheter are indicated for femoral, popliteal, or distal arteries located below the knee. The 2.4 mm Pre-deflected Catheter is indicated for femoral and popliteal arteries only. Refer to product IFU for detailed instructions.
† Grade C or greater
‡ Requiring intervention
1. Rotational atherectomy refers to the Phoenix family of products. 2.4mm deflecting catheter and 2.2 mm auto-deflected catheter have directional cutting ability.
2. Schöfthaler C, Troisi N, Torsello G, Jehn A, Lichtenberg M, Karcher JC, Stavroulakis K, D’Oria M, Saratzis A, Zayed H, Andrassy M, Korosoglou G. Safety and effectiveness of the phoenix atherectomy device for endovascular treatment of common femoral and popliteal arteries: Results of the EN-MOBILE trial. Vasc Med. 2024 Mar 17:1358863X241231943. Doi: 10.1177/1358863X241231943. Epub ahead of print. PMID: 38493349.
3. Davis, Thomas et al., Safety and effectiveness of the Phoenix Atherectomy System in lower extremity arteries: Early and midterm outcomes from the prospective multicenter EASE study. Vascular. September 27, 2017, DOI: 10.1177/1708538117712383. Target lesion locations: ATK (48%) and BTK (52%). Technical success rate was 95.1% (performance goal was 86%). The 2.2 pre-deflected and the 1.5 tracking catheters were determined to be substantially equivalent to the devices studied in the EASE trial.
4. Gandini R, A Single-Center Experience With Phoenix Atherectomy System in Patients With Moderate to ©2021 Heavily Calcified Femoropopliteal Lesions, Cardiovascular Revascularization Medicine 21 (2020), 676–681
5. Giusca S, Safety, effectiveness and mid-term follow-up in 136 consecutive patients with moderate to severely calcified lesions undergoing phoenix atherectomy, Heart and Vessels, Oct 2020
6. Janas A, Comparison of long-term outcomes after directional versus rotational atherectomy in peripheral artery disease, Adv Interv Cardiol 2020; 16, 1 (59): 76–81
7. Giusca S, Hagstotz S, Lichtenberg M, Heinrich U, Eisenbach C, Andrassy M, Korosoglou G. Phoenix atherectomy for patients with peripheral artery disease. EuroIntervention. 2022 Aug 5;18(5):e432-e442. doi: 10.4244/EIJ-D-21-01070. PMID: 35389346.
8. Shishehbor et al. Acute Real-World Outcomes From the Phoenix Post-Approval Registry. J Invasive Cardiol. 2022 Jan;34(1):E1-E7. Epub 2021 Dec 19
9. Kumarasamy A, Gombert A, Krabbe J, Ruprecht O, Jacobs MJ, Krabbe H. Assessment of Feasibility and Patency of below the Knee Atherectomy Using the 1.5 mm Phoenix Catheter-A Retrospective Study. Medicina (Kaunas). 2022 Nov 3;58(11):1594. doi: 10.3390/medicina58111594. PMID: 36363551; PMCID: PMC9699591.
10. Monitor flow of excised material into the disposal reservoir during operation of the Catheter. If flow of excised material ceases during the procedure, this is a sign that the Catheter drive system (cutter, torque shaft, or Handle motor drive) may not be operating properly.
11. Case study results are not predictive. Results in other cases may vary.
12. Center mass cutting device when the guidewire is centered.